Home > Insider Trading > Filing (0001437749-25-021050)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1659617	Moleculin Biotech Inc.	MBRX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
938419	V Walter Klemp	C/O Moleculin Biotech, Inc. 5300 Memorial Dr., Suite 950 Houston TX 77007	Ceo And President	Yes	Yes	No	No

Transaction Summary

Purchased:	675,675 shares	Avg. Price: $0.37	Total Value: $249,999.75
Number of Shares After Transactions:	743,607 shares

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2025-06-20	3,750	$0.00	62,046	No	4	M	Direct
Common Stock	Disposition	2025-06-20	914	$0.27	61,132	No	4	F	Direct
Common Stock	Acquisiton	2025-06-22	8,990	$0.00	70,122	No	4	M	Direct
Common Stock	Disposition	2025-06-22	2,190	$0.27	67,932	No	4	F	Direct
Common Stock	Acquisiton	2025-06-23	675,675	$0.37	743,607	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	F	Direct
No	4	M	Direct
No	4	F	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2025-06-20	3,750	$0.00	3,750	$0.00
Common Stock	Restricted Stock Units	Disposition	2025-06-22	8,990	$0.00	8,990	$0.00
Common Stock	Series E Warrants	Disposition	2025-06-23	2,027,025	$0.00	2,027,025	$0.37

Remaning Holdings	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
391,446	No	4	M	Direct
382,456	No	4	M	Direct
2,409,481	No	4	P	Direct

Footnotes

Restricted stock units convert into common stock on a one-for-one basis.
Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
On June 20, 2022, the reporting person was granted 15,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
On June 22, 2023, the reporting person was granted 35,959 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
On June 23, 2025, the reporting person acquired 675,675 shares of common stock and Series E warrants to purchase 2,027,025 shares of common stock at a purchase price of $0.37 per share and accompanying warrants in a public offering. The Series E warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series E warrants and will expire five years from the date of such approval.